Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies

TLDR

The tumor microenvironment is a dynamic ecosystem that promotes tumor progression and profoundly influences the efficacy of conventional and emerging cancer therapies. The review aims to elucidate how the tumor microenvironment drives metastasis and drug resistance, evaluate therapeutic strategies targeting the TME, and advocate for biomarkers and interdisciplinary approaches to improve personalized cancer treatment. The authors conduct a comprehensive review that examines TME‑driven drug resistance mechanisms, evaluates targeted therapeutic strategies, discusses heterogeneity‑induced treatment variability, and highlights the need for biomarkers and interdisciplinary technologies. By providing critical insights into the current state of TME research and its implications for the future of oncology, the review highlights the dynamic and evolving landscape of this field.

Abstract

This comprehensive review delves into the pivotal role of the tumor microenvironment (TME) in cancer metastasis and therapeutic response, offering fresh insights into the intricate interplay between cancer cells and their surrounding milieu. The TME, a dynamic ecosystem comprising diverse cellular and acellular elements, not only fosters tumor progression but also profoundly affects the efficacy of conventional and emerging cancer therapies. Through nuanced exploration, this review illuminates the multifaceted nature of the TME, elucidating its capacity to engender drug resistance via mechanisms such as hypoxia, immune evasion, and the establishment of physical barriers to drug delivery. Moreover, it investigates innovative therapeutic approaches aimed at targeting the TME, including stromal reprogramming, immune microenvironment modulation, extracellular matrix (ECM)-targeting agents, and personalized medicine strategies, highlighting their potential to augment treatment outcomes. Furthermore, this review critically evaluates the challenges posed by the complexity and heterogeneity of the TME, which contribute to variable therapeutic responses and potentially unintended consequences. This underscores the need to identify robust biomarkers and advance predictive models to anticipate treatment outcomes, as well as advocate for combination therapies that address multiple facets of the TME. Finally, the review emphasizes the necessity of an interdisciplinary approach and the integration of cutting-edge technologies to unravel the intricacies of the TME, thereby facilitating the development of more effective, adaptable, and personalized cancer treatments. By providing critical insights into the current state of TME research and its implications for the future of oncology, this review highlights the dynamic and evolving landscape of this field.